Equillium Announced That Ono Pharmaceutical Has Made The Strategic Business Decision To Allow Its Option To Acquire Equillium's Rights To Itolizumab To Expire
Portfolio Pulse from Benzinga Newsdesk
Equillium announced that Ono Pharmaceutical has decided not to exercise its option to acquire rights to itolizumab. Equillium is now considering accelerating the completion of its Phase 3 EQUATOR study in aGVHD to Q1 2025, with Phase 2 ulcerative colitis study topline data expected in the same quarter.
October 31, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ono Pharmaceutical has decided not to acquire Equillium's rights to itolizumab, impacting Equillium's strategic plans. Equillium is considering accelerating its Phase 3 study timeline.
Ono Pharmaceutical's decision not to acquire rights to itolizumab could be seen as a setback for Equillium, potentially affecting investor sentiment negatively. However, Equillium's plan to accelerate its Phase 3 study could mitigate some concerns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90